Elanco Animal Health

Elanco Animal Health

ELAN · NYSE · Healthcare / Drug Manufacturers - Specialty & Generic

26.78USD+0.28 (+1.06%)

Price History

Full chart

Market Stats

Previous Close26.50
Open26.70
Day Range26.22 – 26.91
52-Week Range19.40 – 27.98
Volume5.38M
Market Cap11.14B
P/E (TTM)0.00
Forward P/E17.36
EPS-0.41
Dividend Yield0.00%
Beta1.68
50-Day Avg24.13
200-Day Avg23.77

About

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Jeffrey N. Simmons
  • Employees9.40K
  • Headquarters450 Elanco Circle, Indianapolis, IN, United States, 46221, USA
  • Websitehttps://www.elanco.com

Leadership

  • Mr. Jeffrey N. SimmonsPresident, CEO & Director · b. 1967
  • Mr. Robert M. VanHimbergenExecutive VP & CFO · b. 1976
  • Dr. Ramiro Martin CabralExecutive VP & President of Elanco International · b. 1972
  • Dr. Ellen de Brabander Ph.D.Executive Vice President of Research, Development & Regulatory Affairs · b. 1963
  • Mr. Timothy J. BettingtonExecutive Vice President of Center of Strategic Growth · b. 1974
  • Mr. James M. MeerSenior VP & Chief Accounting Officer · b. 1970
  • Mr. David S. KinardExecutive Vice President of Human Resources, Corporate Communications & Administration · b. 1967
  • Ms. Tiffany Ann KanagaVP of Investor Relations & ESG
  • Ms. Shiv O'NeillExecutive Vice President, General Counsel & Corporate Secretary · b. 1975
  • Mr. Larbi Van LierSenior Vice President of Asia

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.91B2.91B2.89B3.07B3.07B3.27B4.76B4.41B4.42B4.44B4.71B
Growth (%)-+0.15%-0.84%+6.15%+0.14%+6.59%+45.54%-7.41%+0.14%+0.50%+6.22%
Cost of Revenue1.70B1.58B1.72B1.77B1.67B2.03B2.69B2.44B2.48B2.53B2.67B
Gross Profit1.21B1.33B1.17B1.30B1.40B1.25B2.08B1.97B1.94B1.91B2.05B
Gross Margin41.68%45.78%40.63%42.25%45.60%38.09%43.58%44.66%43.88%43.01%43.48%
Operating Expense1.21B1.05B1.03B981.80M1.03B1.32B1.77B1.59B1.61B1.66B1.80B
Operating Income5.40M283.20M142.40M313.80M370.00M-76.80M304.00M384.00M326.00M251.00M252.00M
Operating Margin0.19%9.72%4.93%10.23%12.05%-2.35%6.38%8.71%7.38%5.65%5.34%
EBITDA-22.60M232.00M85.80M439.70M471.60M900.00K409.00M866.00M-224.00M1.49B676.00M
EBITDA Margin-0.78%7.96%2.97%14.34%15.36%0.03%8.59%19.63%-5.07%33.54%14.34%
Net Income-210.80M-47.90M-310.70M86.50M67.90M-560.10M-483.00M-78.00M-1.23B338.00M-232.00M
Net Income Margin-7.25%-1.64%-10.75%2.82%2.21%-17.11%-10.14%-1.77%-27.87%7.61%-4.92%
R&D291.00M265.80M251.70M246.60M270.10M327.00M369.00M321.00M327.00M344.00M368.00M
R&D as % of Total Revenue10.00%9.12%8.71%8.04%8.80%9.99%7.75%7.28%7.40%7.75%7.80%
Interest Expense00029.60M78.90M156.00M264.00M256.00M277.00M339.00M220.00M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.97%2.57%4.77%5.54%5.80%6.27%7.64%4.67%

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-8.10B8.94B8.96B8.99B17.69B16.48B15.49B14.36B12.61B13.36B
Total Liabilities-1.07B1.15B3.76B3.44B9.22B8.97B8.20B8.14B6.52B6.81B
Total Equity-7.03B7.79B5.20B5.55B8.48B7.51B7.29B6.22B6.10B6.55B
Cash-258.80M323.40M474.80M334.00M495.00M638.00M345.00M352.00M468.00M545.00M
Total Debt---2.47B2.35B6.13B6.32B5.84B5.77B4.32B4.02B
Net Debt--258.80M-323.40M2.00B2.02B5.63B5.68B5.49B5.42B3.85B3.47B

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow6.60M155.90M173.80M487.30M224.10M-41.00M483.00M452.00M271.00M541.00M560.00M
Investing Cash Flow-5.00B-182.10M-964.60M-127.00M-234.80M-4.78B-530.00M-179.00M-169.00M1.16B-279.00M
Financing Cash Flow5.35B-149.60M847.50M-35.20M-304.80M4.95B210.00M-549.00M-83.00M-1.49B-275.00M
Capital Expenditure100.10M110.30M98.60M134.50M197.40M310.90M197.00M184.00M154.00M147.00M276.00M
Free Cash Flow-93.50M45.60M75.20M352.80M26.70M-351.90M286.00M268.00M117.00M394.00M284.00M
FCF to OCF-1416.67%29.25%43.27%72.40%11.91%858.29%59.21%59.29%43.17%72.83%50.71%

Earnings

Report DateSep 21, 2018Nov 6, 2018Feb 6, 2019May 9, 2019Aug 13, 2019Nov 6, 2019Feb 19, 2020May 7, 2020Jul 30, 2020Nov 6, 2020Feb 24, 2021May 7, 2021Aug 9, 2021Nov 5, 2021Feb 24, 2022May 9, 2022Aug 8, 2022Nov 8, 2022Feb 21, 2023May 9, 2023Aug 7, 2023Nov 7, 2023Feb 26, 2024May 8, 2024Aug 8, 2024Nov 7, 2024Feb 24, 2025May 7, 2025Aug 7, 2025Nov 5, 2025Feb 25, 2026May 6, 2026Aug 5, 2026Nov 6, 2026
EPS Estimate0.000.250.270.230.260.260.230.240.070.120.090.230.260.170.170.350.250.160.130.290.050.120.110.270.240.120.150.300.200.130.110.340.270.20
EPS Actual-0.970.290.290.250.280.300.230.130.090.130.120.370.280.190.210.360.360.200.190.450.180.180.080.340.300.130.140.370.260.190.130.400.34-
Surprise-16.00%7.41%8.70%7.69%15.38%0.00%-45.83%28.57%8.33%33.33%60.87%7.69%11.76%23.53%2.86%44.00%25.00%46.15%55.17%260.00%50.00%-27.27%25.93%25.00%8.33%-5.79%23.33%30.00%46.15%14.54%17.65%25.93%-
TimingAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap11.14B
Enterprise Value14.66B
Trailing P/E0.00
Forward P/E17.36
PEG Ratio4.04
Price / Sales2.22
Price / Book1.71
EPS-0.41
Book Value13.19
Revenue (TTM)5.02B
Gross Profit (TTM)2.78B
EBITDA1.01B
Profit Margin-3.96%
Operating Margin8.63%
Return on Equity-2.98%
Return on Assets1.56%
Shares Outstanding499.45M
Shares Float495.40M
Beta1.68
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 15 analystsTarget 31.21
  • Strong Buy
    6
  • Buy
    1
  • Hold
    8

Ownership Breakdown

Institutions
115.32%
Insiders
1.23%
Retail / Other
0.00%

Top Institutional Holders

  • Dodge & Cox
    67.40M13.49%
  • FMR Inc
    50.93M10.19%
  • BlackRock Inc
    47.62M9.53%
  • PRIMECAP Management Company
    45.45M9.10%
  • T. Rowe Price Investment Management,Inc.
    34.64M6.93%
  • Dimensional Fund Advisors, Inc.
    25.42M5.09%
  • Vanguard Portfolio Management, LLC
    22.64M4.53%
  • Vanguard Capital Management, LLC
    22.34M4.47%
  • State Street Corp
    15.34M3.07%
  • Winslow Capital Management, LLC
    13.51M2.70%
  • Geode Capital Management, LLC
    11.19M2.24%
  • Black Creek Investment Management Inc
    10.49M2.10%
  • Citadel Advisors Llc
    9.67M1.94%

Top Fund Holders

  • Dodge & Cox Stock I
    43.11M8.63%
  • Vanguard PRIMECAP Inv
    17.75M3.55%
  • iShares Core S&P Mid-Cap ETF
    17.49M3.50%
  • Vanguard MStar Total Stk Mkt Idx Invest
    15.91M3.18%
  • Vanguard Small Cap Index
    11.49M2.30%
  • Vanguard Capital Opportunity Inv
    10.16M2.03%
  • T. Rowe Price Mid-Cap Growth
    9.55M1.91%